NHS National Framework Agreement for Omalizumab
NHS England is establishing a national framework agreement for supply of omalizumab, a biologic used to treat severe asthma and other conditions. The contract runs from February 2026 to August 2027 with optional extensions of up to 24 months.
- Closed30 October 2025
- Value£86m
- BuyerNHS England
- CategoryHealth & medical
- RegionUK-wide
You'll want to look if you are a pharmaceutical company licensed to supply omalizumab in the UK and capable of meeting NHS procurement standards.
Might not suit a small firm
- the contract itself is a large one
- it needs coverage across the whole UK